Shaolin Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shaolin Liang has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Yunqi Zhang
Digital Health Lab, Institute for Six-sector Economy, Fudan University, Shanghai, China
4 shared publications - Yanping Li
Reproductive Medicine Center, Xiangya Hospital of Central South University, Changsha, People’s Republic of China
3 shared publications - Bin Xu
Department of Reproductive Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China
2 shared publications - Ge Yang
Division of Neonatology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong, China
2 shared publications - Hongying Tang
Department of Reproductive Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China
2 shared publications - Hui Li
Department of Reproductive Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China
2 shared publications
Latest Publications
- 16 April 2026
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 11 (5) , 3653-3663
Voltammetric Analysis of Quasi-Reversible Kinetics in Aptamer Self-Assembled Monolayers: Toward Rational E-AB Sensor Design
Electrochemical aptamer-based (E-AB) sensors are surface-bound systems, in which electron-transfer kinetics are quasi-reversible on typical measurement timescales. This combination represents a critical process; therefore, a systematic understanding of these processes is essential for the rational design and performance optimization of E-AB sensors; however, thorough investigations in this area remain limited. Here, we present a comprehensive voltammetric characterization of an E-AB sensor to detect vancomycin as a model target. By employing cyclic voltammetry (CV) and square wave voltammetry (SWV), we delineate how the charge transfer kinetics and aptamer conformational dynamics influence the overall sensor response. A detailed analysis of the cyclic voltammetry (CV) results, using the Laviron method and peak-to-peak separation trends, enables quantification of the heterogeneous electron-transfer rate constants (ks) in the target-free (“unbound”) state as ks, ox = 10.3 ± 3.3 s−1 and ks, red = 6.8 ± 2.2 s−1; in contrast, target binding increased these values, reaching ks, ox = 43.6 ± 14.8 s−1 and ks, red = 45.6 ± 11 s−1. Additionally, our analysis reveals that aptamer packing density cannot be measured independently from the sensor’s peak current, highlighting the necessity for a calibration approach independent of aptamer surface coverage. We further demonstrate a ratiometric SWV approach using two distinct frequencies, enabling robust calibration and mitigating sensor-to-sensor variability. This method reduced the relative standard deviation (RSD) to 2.2% (n = 9 sensors) compared to 10.5% for absolute current values. Taken together, this work provides insights into E-AB sensor operation, facilitating rational optimization of sensor design and interrogation strategies for clinical and industrial applications.
- 16 April 2026
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 11 (5) , 3653-3663
Voltammetric Analysis of Quasi-Reversible Kinetics in Aptamer Self-Assembled Monolayers: Toward Rational E-AB Sensor Design
Electrochemical aptamer-based (E-AB) sensors are surface-bound systems, in which electron-transfer kinetics are quasi-reversible on typical measurement timescales. This combination represents a critical process; therefore, a systematic understanding of these processes is essential for the rational design and performance optimization of E-AB sensors; however, thorough investigations in this area remain limited. Here, we present a comprehensive voltammetric characterization of an E-AB sensor to detect vancomycin as a model target. By employing cyclic voltammetry (CV) and square wave voltammetry (SWV), we delineate how the charge transfer kinetics and aptamer conformational dynamics influence the overall sensor response. A detailed analysis of the cyclic voltammetry (CV) results, using the Laviron method and peak-to-peak separation trends, enables quantification of the heterogeneous electron-transfer rate constants (ks) in the target-free (“unbound”) state as ks, ox = 10.3 ± 3.3 s−1 and ks, red = 6.8 ± 2.2 s−1; in contrast, target binding increased these values, reaching ks, ox = 43.6 ± 14.8 s−1 and ks, red = 45.6 ± 11 s−1. Additionally, our analysis reveals that aptamer packing density cannot be measured independently from the sensor’s peak current, highlighting the necessity for a calibration approach independent of aptamer surface coverage. We further demonstrate a ratiometric SWV approach using two distinct frequencies, enabling robust calibration and mitigating sensor-to-sensor variability. This method reduced the relative standard deviation (RSD) to 2.2% (n = 9 sensors) compared to 10.5% for absolute current values. Taken together, this work provides insights into E-AB sensor operation, facilitating rational optimization of sensor design and interrogation strategies for clinical and industrial applications.
- Open Access
Association between epidural analgesia experience and future fertility intention in China: a national cross-sectional study
Objectives To assess the association between epidural analgesia (EDA) experience and subsequent fertility intention among reproductive-aged individuals with at least one child in China, and to examine whether this relationship varies by region and parity. Design This nationwide cross-sectional study was conducted using multistage stratified and quota sampling across 148 cities in mainland China. Data were analysed using descriptive statistics, generalised linear models and multinomial logistic regression (Mlogit). Setting Community-based data collection conducted across 148 cities in mainland China between 20 June and 31 August 2022. Participants Of 21 872 respondents, 6349 reproductive-aged individuals (females aged 18–49 and males aged 18–65) with at least one child were included after applying standardised data quality criteria. Primary and secondary outcome measures The primary outcome was self-rated fertility intention, operationalised as a continuous measure for regression analysis. The main exposure variable was prior experience with EDA during vaginal birth. Secondary analyses explored variations by region and number of children. Results EDA experience was positively associated with higher fertility intention (β=0.067, 95% CI 0.007 to 0.126, p=0.028). Female respondents reported lower fertility intention compared with males. Regionally, significant positive associations were observed in the central (relative risk ratio (RRR)=1.433, 95% CI 1.011 to 2.032, p=0.043) and western regions (RRR=1.505, 95% CI 1.070 to 2.117, p=0.019). Among women, EDA use was significantly associated with increased fertility intention in primigravida but not in multigravida participants. Conclusions EDA use is positively associated with fertility intention among Chinese reproductive-aged individuals with children. Although this study identifies an association rather than a causal relationship—given the cross-sectional design—it highlights the potential value of improving awareness and access to labour pain management, especially in less developed regions, to better support informed reproductive decision-making and childbirth experiences. Trial registration number ChiCTR2200061046.
Open AccessAssociation between epidural analgesia experience and future fertility intention in China: a national cross-sectional study
Objectives To assess the association between epidural analgesia (EDA) experience and subsequent fertility intention among reproductive-aged individuals with at least one child in China, and to examine whether this relationship varies by region and parity. Design This nationwide cross-sectional study was conducted using multistage stratified and quota sampling across 148 cities in mainland China. Data were analysed using descriptive statistics, generalised linear models and multinomial logistic regression (Mlogit). Setting Community-based data collection conducted across 148 cities in mainland China between 20 June and 31 August 2022. Participants Of 21 872 respondents, 6349 reproductive-aged individuals (females aged 18–49 and males aged 18–65) with at least one child were included after applying standardised data quality criteria. Primary and secondary outcome measures The primary outcome was self-rated fertility intention, operationalised as a continuous measure for regression analysis. The main exposure variable was prior experience with EDA during vaginal birth. Secondary analyses explored variations by region and number of children. Results EDA experience was positively associated with higher fertility intention (β=0.067, 95% CI 0.007 to 0.126, p=0.028). Female respondents reported lower fertility intention compared with males. Regionally, significant positive associations were observed in the central (relative risk ratio (RRR)=1.433, 95% CI 1.011 to 2.032, p=0.043) and western regions (RRR=1.505, 95% CI 1.070 to 2.117, p=0.019). Among women, EDA use was significantly associated with increased fertility intention in primigravida but not in multigravida participants. Conclusions EDA use is positively associated with fertility intention among Chinese reproductive-aged individuals with children. Although this study identifies an association rather than a causal relationship—given the cross-sectional design—it highlights the potential value of improving awareness and access to labour pain management, especially in less developed regions, to better support informed reproductive decision-making and childbirth experiences. Trial registration number ChiCTR2200061046.
- Open Access
- 3 February 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e78245
Integrated Prediction System for Individualized Ovarian Stimulation and Ovarian Hyperstimulation Syndrome Prevention: Algorithm Development and Validation
Background: Accurately predicting ovarian response and determining the optimal starting dose of follicle-stimulating hormone (FSH) remain critical yet challenging for effective ovarian stimulation. Currently, there is a lack of a comprehensive model capable of simultaneously forecasting the number of oocytes retrieved (NOR) and assessing the risk of early-onset moderate-to-severe ovarian hyperstimulation syndrome (OHSS). Objective: This study aimed to establish an integrated mode capable of forecasting the NOR and assessing the risk of early-onset moderate-to-severe OHSS across varying starting doses of FSH. Methods: This prognostic study included patients undergoing their first ovarian stimulation cycles at 2 independent in vitro fertilization clinics. Automated classifiers were used for variable selection. Machine learning models (11 for NOR and 11 for OHSS) were developed and validated using internal (n=6401) and external (n=3805) datasets. Shapley additive explanation was applied for variable interpretation. The best-performing models were incorporated into a web-based prediction tool. Results: For NOR prediction, 17 variables were selected, with the gradient boosting regressor achieving the highest performance (internal dataset: R2=0.7978; external dataset: R2=0.7924). For OHSS prediction, 19 variables were identified, and the LightGBM model demonstrated superior performance (internal dataset: area under the receiver operating characteristic curve=0.7588; external dataset: area under the receiver operating characteristic curve=0.7287). Shapley additive explanation analysis highlighted the FSH starting dose to BMI ratio and baseline antral follicle count as key predictors for NOR and OHSS, respectively. Dose-response curves were generated to visualize predicted outcomes with varying FSH starting doses. The models were implemented in a user-friendly, research-oriented online prototype, individualized ovarian stimulation guide (InOvaSGuide). Conclusions: This study introduces an integrated framework for predicting NOR and early-onset moderate-to-severe OHSS risk across different FSH doses. Future prospective evaluation is needed before clinical implementation.
- 3 February 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e78245
Open AccessIntegrated Prediction System for Individualized Ovarian Stimulation and Ovarian Hyperstimulation Syndrome Prevention: Algorithm Development and Validation
Background: Accurately predicting ovarian response and determining the optimal starting dose of follicle-stimulating hormone (FSH) remain critical yet challenging for effective ovarian stimulation. Currently, there is a lack of a comprehensive model capable of simultaneously forecasting the number of oocytes retrieved (NOR) and assessing the risk of early-onset moderate-to-severe ovarian hyperstimulation syndrome (OHSS). Objective: This study aimed to establish an integrated mode capable of forecasting the NOR and assessing the risk of early-onset moderate-to-severe OHSS across varying starting doses of FSH. Methods: This prognostic study included patients undergoing their first ovarian stimulation cycles at 2 independent in vitro fertilization clinics. Automated classifiers were used for variable selection. Machine learning models (11 for NOR and 11 for OHSS) were developed and validated using internal (n=6401) and external (n=3805) datasets. Shapley additive explanation was applied for variable interpretation. The best-performing models were incorporated into a web-based prediction tool. Results: For NOR prediction, 17 variables were selected, with the gradient boosting regressor achieving the highest performance (internal dataset: R2=0.7978; external dataset: R2=0.7924). For OHSS prediction, 19 variables were identified, and the LightGBM model demonstrated superior performance (internal dataset: area under the receiver operating characteristic curve=0.7588; external dataset: area under the receiver operating characteristic curve=0.7287). Shapley additive explanation analysis highlighted the FSH starting dose to BMI ratio and baseline antral follicle count as key predictors for NOR and OHSS, respectively. Dose-response curves were generated to visualize predicted outcomes with varying FSH starting doses. The models were implemented in a user-friendly, research-oriented online prototype, individualized ovarian stimulation guide (InOvaSGuide). Conclusions: This study introduces an integrated framework for predicting NOR and early-onset moderate-to-severe OHSS risk across different FSH doses. Future prospective evaluation is needed before clinical implementation.
- Open Access
- 30 May 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Integrated Prediction System for Individualized Ovarian Stimulation and Ovarian Hyperstimulation Syndrome Prevention: Algorithm Development and Validation (Preprint)
BACKGROUND Accurately predicting ovarian response and determining the optimal starting dose of follicle-stimulating hormone (FSH) remain critical yet challenging for effective ovarian stimulation. Currently, there is a lack of a comprehensive model capable of simultaneously forecasting the number of oocytes retrieved (NOR) and assessing the risk of early-onset moderate-to-severe ovarian hyperstimulation syndrome (OHSS). OBJECTIVE This study aimed to establish an integrated mode capable of forecasting the NOR and assessing the risk of early-onset moderate-to-severe OHSS across varying starting doses of FSH. METHODS This prognostic study included patients undergoing their first ovarian stimulation cycles at 2 independent in vitro fertilization clinics. Automated classifiers were used for variable selection. Machine learning models (11 for NOR and 11 for OHSS) were developed and validated using internal (n=6401) and external (n=3805) datasets. Shapley additive explanation was applied for variable interpretation. The best-performing models were incorporated into a web-based prediction tool. RESULTS For NOR prediction, 17 variables were selected, with the gradient boosting regressor achieving the highest performance (internal dataset: R2=0.7978; external dataset: R2=0.7924). For OHSS prediction, 19 variables were identified, and the LightGBM model demonstrated superior performance (internal dataset: area under the receiver operating characteristic curve=0.7588; external dataset: area under the receiver operating characteristic curve=0.7287). Shapley additive explanation analysis highlighted the FSH starting dose to BMI ratio and baseline antral follicle count as key predictors for NOR and OHSS, respectively. Dose-response curves were generated to visualize predicted outcomes with varying FSH starting doses. The models were implemented in a user-friendly, research-oriented online prototype, individualized ovarian stimulation guide (InOvaSGuide). CONCLUSIONS This study introduces an integrated framework for predicting NOR and early-onset moderate-to-severe OHSS risk across different FSH doses. Future prospective evaluation is needed before clinical implementation.
- 30 May 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessIntegrated Prediction System for Individualized Ovarian Stimulation and Ovarian Hyperstimulation Syndrome Prevention: Algorithm Development and Validation (Preprint)
BACKGROUND Accurately predicting ovarian response and determining the optimal starting dose of follicle-stimulating hormone (FSH) remain critical yet challenging for effective ovarian stimulation. Currently, there is a lack of a comprehensive model capable of simultaneously forecasting the number of oocytes retrieved (NOR) and assessing the risk of early-onset moderate-to-severe ovarian hyperstimulation syndrome (OHSS). OBJECTIVE This study aimed to establish an integrated mode capable of forecasting the NOR and assessing the risk of early-onset moderate-to-severe OHSS across varying starting doses of FSH. METHODS This prognostic study included patients undergoing their first ovarian stimulation cycles at 2 independent in vitro fertilization clinics. Automated classifiers were used for variable selection. Machine learning models (11 for NOR and 11 for OHSS) were developed and validated using internal (n=6401) and external (n=3805) datasets. Shapley additive explanation was applied for variable interpretation. The best-performing models were incorporated into a web-based prediction tool. RESULTS For NOR prediction, 17 variables were selected, with the gradient boosting regressor achieving the highest performance (internal dataset: R2=0.7978; external dataset: R2=0.7924). For OHSS prediction, 19 variables were identified, and the LightGBM model demonstrated superior performance (internal dataset: area under the receiver operating characteristic curve=0.7588; external dataset: area under the receiver operating characteristic curve=0.7287). Shapley additive explanation analysis highlighted the FSH starting dose to BMI ratio and baseline antral follicle count as key predictors for NOR and OHSS, respectively. Dose-response curves were generated to visualize predicted outcomes with varying FSH starting doses. The models were implemented in a user-friendly, research-oriented online prototype, individualized ovarian stimulation guide (InOvaSGuide). CONCLUSIONS This study introduces an integrated framework for predicting NOR and early-onset moderate-to-severe OHSS risk across different FSH doses. Future prospective evaluation is needed before clinical implementation.
- Open Access
- 11 July 2024
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 13 (1) , e48259
Evolution of Digital Health and Exploration of Patented Technologies (2017-2021): Bibliometric Analysis
Background: The significant impact of digital health emerged prominently during the COVID-19 pandemic. Despite this, there is a paucity of bibliometric analyses focusing on technologies within the field of digital health patents. Patents offer a wealth of insights into technologies, commercial prospects, and competitive landscapes, often undisclosed in other publications. Given the rapid evolution of the digital health industry, safeguarding algorithms, software, and advanced surgical devices through patent systems is imperative. The patent system simultaneously acts as a valuable repository of technological knowledge, accessible to researchers. This accessibility facilitates the enhancement of existing technologies and the advancement of medical equipment, ultimately contributing to public health improvement and meeting public demands. Objective: The primary objective of this study is to gain a more profound understanding of technology hotspots and development trends within the field of digital health. Methods: Using a bibliometric analysis methodology, we assessed the global technological output reflected in patents on digital health published between 2017 and 2021. Using Citespace5.1R8 and Excel 2016, we conducted bibliometric visualization and comparative analyses of key metrics, including national contributions, institutional affiliations, inventor profiles, and technology topics. Results: A total of 15,763 digital health patents were identified as published between 2017 and 2021. The China National Intellectual Property Administration secured the top position with 7253 published patents, whereas Koninklijke Philips emerged as the leading institution with 329 patents. Notably, Assaf Govari emerged as the most prolific inventor. Technology hot spots encompassed categories such as “Medical Equipment and Information Systems,” “Image Analysis,” and “Electrical Diagnosis,” classified by Derwent Manual Code. A patent related to the technique of receiving and transmitting data through microchips garnered the highest citation, attributed to the patentee Covidien LP. Conclusions: The trajectory of digital health patents has been growing since 2017, primarily propelled by China, the United States, and Japan. Applications in health interventions and enhancements in surgical devices represent the predominant scenarios for digital health technology. Algorithms emerged as the pivotal technologies protected by patents, whereas techniques related to data transfer, storage, and exchange in the digital health domain are anticipated to be focal points in forthcoming basic research.
- 11 July 2024
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 13 (1) , e48259
Open AccessEvolution of Digital Health and Exploration of Patented Technologies (2017-2021): Bibliometric Analysis
Background: The significant impact of digital health emerged prominently during the COVID-19 pandemic. Despite this, there is a paucity of bibliometric analyses focusing on technologies within the field of digital health patents. Patents offer a wealth of insights into technologies, commercial prospects, and competitive landscapes, often undisclosed in other publications. Given the rapid evolution of the digital health industry, safeguarding algorithms, software, and advanced surgical devices through patent systems is imperative. The patent system simultaneously acts as a valuable repository of technological knowledge, accessible to researchers. This accessibility facilitates the enhancement of existing technologies and the advancement of medical equipment, ultimately contributing to public health improvement and meeting public demands. Objective: The primary objective of this study is to gain a more profound understanding of technology hotspots and development trends within the field of digital health. Methods: Using a bibliometric analysis methodology, we assessed the global technological output reflected in patents on digital health published between 2017 and 2021. Using Citespace5.1R8 and Excel 2016, we conducted bibliometric visualization and comparative analyses of key metrics, including national contributions, institutional affiliations, inventor profiles, and technology topics. Results: A total of 15,763 digital health patents were identified as published between 2017 and 2021. The China National Intellectual Property Administration secured the top position with 7253 published patents, whereas Koninklijke Philips emerged as the leading institution with 329 patents. Notably, Assaf Govari emerged as the most prolific inventor. Technology hot spots encompassed categories such as “Medical Equipment and Information Systems,” “Image Analysis,” and “Electrical Diagnosis,” classified by Derwent Manual Code. A patent related to the technique of receiving and transmitting data through microchips garnered the highest citation, attributed to the patentee Covidien LP. Conclusions: The trajectory of digital health patents has been growing since 2017, primarily propelled by China, the United States, and Japan. Applications in health interventions and enhancements in surgical devices represent the predominant scenarios for digital health technology. Algorithms emerged as the pivotal technologies protected by patents, whereas techniques related to data transfer, storage, and exchange in the digital health domain are anticipated to be focal points in forthcoming basic research.
- Open Access
- 1 September 2023
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 21 (1) , 1-10
Hyperbaric oxygen therapy: a possible choice for patients with resistant thin endometrium during frozen embryo transfer treatments
Background: Thin endometrium is considered suboptimal for embryo implantation, leading to compromised pregnancy rates without effective therapies. While some studies have reported promoted endometrial growth after a period of hyperbaric oxygen therapy (HBOT) in patients with intrauterine adhesion, there have been no reports in patients with resistant thin endometrium. The purpose of this study was to investigate the impact of HBOT on endometrium growth and pregnancy outcomes in patients with resistant thin endometrium during frozen embryo transfer (FET) treatments. Methods: This prospective pre-post cohort study was conducted at a university-affiliated assisted reproductive medical center between October 2021 and December 2022. Patients who had experienced at least one canceled transfer cycle due to a thin endometrium(< 7 mm) on the endometrium transformation day, despite the use of standard therapies as well as adjuvant therapies, were enrolled in the study. Patients were assigned voluntarily to either the HBOT group or the concurrent control group. The HBOT group received daily HBOT for at least 10 days during the proliferative phase, in addition to the routine endometrium preparation methods and the concurrent control group underwent cycles without HBOT. Propensity score matching (PSM) was used to ensure comparability between the groups. Both self-control and case-control comparisons were conducted. The primary outcome measured was endometrial thickness (ET) on the day of endometrium transformation. Secondary outcomes included intrauterine pregnancy rate (IPR), embryo implantation rate (IR), miscarriage rate, and others. Results: Patients in the HBOT group demonstrated a significantly thicker endometrial thickness on the day of endometrium transformation after undergoing therapy (5.76 ± 1.66 vs. 6.57 ± 1.23, P = 0.002). This improvement was accompanied by a decreased rate of cycle cancellations. Baseline parameters and endometrial thickness were comparable between the HBOT group and the concurrent control group during the cycle. The IPR was similar in patients who received cleavage-stage embryos (0.0% vs. 6.7%, P = 1.00), but significantly higher in patients in the HBOT group who received blastocysts (53.8% vs. 18.2%, P = 0.017). Conclusions: A period of HBOT prior to endometrium transformation contributes to increased endometrial thickness and facilitates blastocyst implantation in patients with resistant thin endometrium during FET treatments. Trial registration: The trial was registered on the Chinese Clinical Trial Registry (registration no. ChiCTR2300072831, retrospectively registered).
- 1 September 2023
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 21 (1) , 1-10
Open AccessHyperbaric oxygen therapy: a possible choice for patients with resistant thin endometrium during frozen embryo transfer treatments
Background: Thin endometrium is considered suboptimal for embryo implantation, leading to compromised pregnancy rates without effective therapies. While some studies have reported promoted endometrial growth after a period of hyperbaric oxygen therapy (HBOT) in patients with intrauterine adhesion, there have been no reports in patients with resistant thin endometrium. The purpose of this study was to investigate the impact of HBOT on endometrium growth and pregnancy outcomes in patients with resistant thin endometrium during frozen embryo transfer (FET) treatments. Methods: This prospective pre-post cohort study was conducted at a university-affiliated assisted reproductive medical center between October 2021 and December 2022. Patients who had experienced at least one canceled transfer cycle due to a thin endometrium(< 7 mm) on the endometrium transformation day, despite the use of standard therapies as well as adjuvant therapies, were enrolled in the study. Patients were assigned voluntarily to either the HBOT group or the concurrent control group. The HBOT group received daily HBOT for at least 10 days during the proliferative phase, in addition to the routine endometrium preparation methods and the concurrent control group underwent cycles without HBOT. Propensity score matching (PSM) was used to ensure comparability between the groups. Both self-control and case-control comparisons were conducted. The primary outcome measured was endometrial thickness (ET) on the day of endometrium transformation. Secondary outcomes included intrauterine pregnancy rate (IPR), embryo implantation rate (IR), miscarriage rate, and others. Results: Patients in the HBOT group demonstrated a significantly thicker endometrial thickness on the day of endometrium transformation after undergoing therapy (5.76 ± 1.66 vs. 6.57 ± 1.23, P = 0.002). This improvement was accompanied by a decreased rate of cycle cancellations. Baseline parameters and endometrial thickness were comparable between the HBOT group and the concurrent control group during the cycle. The IPR was similar in patients who received cleavage-stage embryos (0.0% vs. 6.7%, P = 1.00), but significantly higher in patients in the HBOT group who received blastocysts (53.8% vs. 18.2%, P = 0.017). Conclusions: A period of HBOT prior to endometrium transformation contributes to increased endometrial thickness and facilitates blastocyst implantation in patients with resistant thin endometrium during FET treatments. Trial registration: The trial was registered on the Chinese Clinical Trial Registry (registration no. ChiCTR2300072831, retrospectively registered).
- Open Access
- 18 April 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Evolution of Digital Health and Exploration of Patented Technologies (2017-2021): Bibliometric Analysis (Preprint)
BACKGROUND The significant impact of digital health emerged prominently during the COVID-19 pandemic. Despite this, there is a paucity of bibliometric analyses focusing on technologies within the field of digital health patents. Patents offer a wealth of insights into technologies, commercial prospects, and competitive landscapes, often undisclosed in other publications. Given the rapid evolution of the digital health industry, safeguarding algorithms, software, and advanced surgical devices through patent systems is imperative. The patent system simultaneously acts as a valuable repository of technological knowledge, accessible to researchers. This accessibility facilitates the enhancement of existing technologies and the advancement of medical equipment, ultimately contributing to public health improvement and meeting public demands. OBJECTIVE The primary objective of this study is to gain a more profound understanding of technology hotspots and development trends within the field of digital health. METHODS Using a bibliometric analysis methodology, we assessed the global technological output reflected in patents on digital health published between 2017 and 2021. Using Citespace5.1R8 and Excel 2016, we conducted bibliometric visualization and comparative analyses of key metrics, including national contributions, institutional affiliations, inventor profiles, and technology topics. RESULTS A total of 15,763 digital health patents were identified as published between 2017 and 2021. The China National Intellectual Property Administration secured the top position with 7253 published patents, whereas Koninklijke Philips emerged as the leading institution with 329 patents. Notably, Assaf Govari emerged as the most prolific inventor. Technology hot spots encompassed categories such as “Medical Equipment and Information Systems,” “Image Analysis,” and “Electrical Diagnosis,” classified by Derwent Manual Code. A patent related to the technique of receiving and transmitting data through microchips garnered the highest citation, attributed to the patentee Covidien LP. CONCLUSIONS The trajectory of digital health patents has been growing since 2017, primarily propelled by China, the United States, and Japan. Applications in health interventions and enhancements in surgical devices represent the predominant scenarios for digital health technology. Algorithms emerged as the pivotal technologies protected by patents, whereas techniques related to data transfer, storage, and exchange in the digital health domain are anticipated to be focal points in forthcoming basic research.
- 18 April 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEvolution of Digital Health and Exploration of Patented Technologies (2017-2021): Bibliometric Analysis (Preprint)
BACKGROUND The significant impact of digital health emerged prominently during the COVID-19 pandemic. Despite this, there is a paucity of bibliometric analyses focusing on technologies within the field of digital health patents. Patents offer a wealth of insights into technologies, commercial prospects, and competitive landscapes, often undisclosed in other publications. Given the rapid evolution of the digital health industry, safeguarding algorithms, software, and advanced surgical devices through patent systems is imperative. The patent system simultaneously acts as a valuable repository of technological knowledge, accessible to researchers. This accessibility facilitates the enhancement of existing technologies and the advancement of medical equipment, ultimately contributing to public health improvement and meeting public demands. OBJECTIVE The primary objective of this study is to gain a more profound understanding of technology hotspots and development trends within the field of digital health. METHODS Using a bibliometric analysis methodology, we assessed the global technological output reflected in patents on digital health published between 2017 and 2021. Using Citespace5.1R8 and Excel 2016, we conducted bibliometric visualization and comparative analyses of key metrics, including national contributions, institutional affiliations, inventor profiles, and technology topics. RESULTS A total of 15,763 digital health patents were identified as published between 2017 and 2021. The China National Intellectual Property Administration secured the top position with 7253 published patents, whereas Koninklijke Philips emerged as the leading institution with 329 patents. Notably, Assaf Govari emerged as the most prolific inventor. Technology hot spots encompassed categories such as “Medical Equipment and Information Systems,” “Image Analysis,” and “Electrical Diagnosis,” classified by Derwent Manual Code. A patent related to the technique of receiving and transmitting data through microchips garnered the highest citation, attributed to the patentee Covidien LP. CONCLUSIONS The trajectory of digital health patents has been growing since 2017, primarily propelled by China, the United States, and Japan. Applications in health interventions and enhancements in surgical devices represent the predominant scenarios for digital health technology. Algorithms emerged as the pivotal technologies protected by patents, whereas techniques related to data transfer, storage, and exchange in the digital health domain are anticipated to be focal points in forthcoming basic research.